RE: NEWS!!AZD103 to get P2 for another Indication
Don't forget Minozac winer.....or Optimol for that matter.
Diabetes Program in support of Phasell TT-223 in Type2 Diabetes is in full swing. Started even before Novo was given notice. SAD study is COMPLETE. MAD Study is ONGOING.
$4million for Type1 Diabetes GLP1+TT-223 in partnership with Juvenile Diabetes Foundation....the JDRF.
You're right price doesn't reflect many of these things.
Orla's numbers extrapolate to $34.50/share just for AZD-103 at this stage of the game of Phasell's. If Transition Applies for Approval for AZD-103 from the Phasell Data her Probability of Success rockets up to 60%. That's $69.13/share with Transition owning just 30%........Recall Transition intends on increasing their share up from the current 30%........do the math.